NYSE:NVTA - Invitae Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $42.44
  • Forecasted Upside: 25.54 %
  • Number of Analysts: 10
  • Breakdown:
  • 0 Sell Ratings
  • 5 Hold Ratings
  • 5 Buy Ratings
  • 0 Strong Buy Ratings
▲ +0.69 (2.08%)

This chart shows the closing price for NVTA by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Invitae Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for NVTA and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for NVTA

Analyst Price Target is $42.44
▲ +25.54% Upside Potential
This price target is based on 10 analysts offering 12 month price targets for Invitae in the last 3 months. The average price target is $42.44, with a high forecast of $58.00 and a low forecast of $33.00. The average price target represents a 25.54% upside from the last price of $33.81.

This chart shows the closing price for NVTA for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 10 investment analysts is to buy stock in Invitae. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart

  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 4 buy ratings
  • 2 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 4 buy ratings
  • 3 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 4 buy ratings
  • 3 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 4 buy ratings
  • 3 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 5 buy ratings
  • 5 hold ratings
  • 0 sell ratings

Latest Recommendations

  • 0 strong buy ratings
  • 5 buy ratings
  • 5 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
6/21/2021Wells Fargo & CompanyBoost Price TargetEqual Weight$30.00 ➝ $35.00Low
6/15/2021Raymond JamesInitiated CoverageOutperform$37.00Medium
6/3/2021The Goldman Sachs GroupInitiated CoverageNeutral$33.00High
5/25/2021Wells Fargo & CompanyInitiated CoverageEqual Weight$30.00High
5/6/2021Morgan StanleyLower Price TargetEqual Weight$45.00 ➝ $41.00High
5/5/2021SVB LeerinkLower Price TargetOutperform$65.00 ➝ $50.00High
4/11/2021SVB LeerinkReiterated RatingBuyLow
4/5/2021OppenheimerUpgradeMarket Perform ➝ Outperform$48.00High
2/25/2021Morgan StanleyBoost Price TargetEqual Weight$41.00 ➝ $45.00High
2/18/2021SVB LeerinkBoost Price TargetOutperform$64.00 ➝ $65.00High
2/18/2021LADENBURG THALM/SH SHUpgradeNeutral ➝ Buy$46.50 ➝ $58.00High
2/1/2021OppenheimerDowngradeOutperform ➝ Market PerformLow
1/20/2021SVB LeerinkBoost Price TargetOutperform$48.00 ➝ $64.00Low
11/6/2020Morgan StanleyBoost Price TargetEqual Weight$38.00 ➝ $41.00Medium
11/6/2020LADENBURG THALM/SH SHDowngradeBuy ➝ NeutralLow
11/3/2020SVB LeerinkBoost Price TargetOutperform$34.00 ➝ $44.00High
10/14/2020JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral$45.00High
10/5/2020OppenheimerBoost Price Target$37.00 ➝ $48.00Medium
9/9/2020Morgan StanleyInitiated CoverageEqual Weight$38.00High
8/5/2020LADENBURG THALM/SH SHBoost Price TargetBuy$31.25 ➝ $37.25High
8/5/2020SVB LeerinkLower Price TargetOutperform$40.00 ➝ $34.00High
8/4/2020OppenheimerInitiated CoverageBuy$37.00High
7/21/2020OppenheimerInitiated CoveragePositive ➝ Buy$29.00 ➝ $37.00Low
7/15/2020SVB LeerinkBoost Price TargetOutperform$25.00 ➝ $40.00Medium
7/1/2020BenchmarkDowngradeBuy ➝ HoldMedium
6/26/2020CowenBoost Price TargetOutperform$18.00 ➝ $35.00Medium
6/22/2020OppenheimerReiterated RatingBuy$29.00High
5/6/2020SVB LeerinkBoost Price TargetOutperform$20.00 ➝ $25.00High
4/8/2020BenchmarkLower Price TargetBuy$31.00 ➝ $20.00High
4/2/2020OppenheimerLower Price Target$32.00 ➝ $25.00High
2/20/2020CowenBoost Price TargetOutperform ➝ In-Line$20.00 ➝ $30.00High
8/25/2019Chardan CapitalSet Price TargetBuy$32.00High
8/7/2019SVB LeerinkSet Price TargetBuy$31.00Medium
8/7/2019OppenheimerSet Price TargetBuy$34.00Medium
8/7/2019BenchmarkReiterated RatingBuy ➝ Buy$26.00 ➝ $28.00High
7/12/2019BenchmarkBoost Price TargetBuy$22.00 ➝ $26.00Low
6/11/2019Chardan CapitalReiterated RatingBuy$30.00High
4/8/2019OppenheimerBoost Price TargetOutperform$21.00 ➝ $30.00Medium
3/4/2019Chardan CapitalInitiated CoverageBuy ➝ Buy$29.00Low
2/20/2019BenchmarkBoost Price TargetBuy$17.00 ➝ $20.00High
2/20/2019JPMorgan Chase & Co.Reiterated RatingOverweight$20.00High
12/19/2018CIBCInitiated CoverageOutperform ➝ OutperformHigh
12/19/2018OppenheimerInitiated CoverageOutperform$20.00High
11/20/2018BenchmarkInitiated CoverageBuy ➝ Buy$17.00High
11/8/2018William BlairReiterated RatingMarket PerformLow
11/8/2018JPMorgan Chase & Co.Boost Price TargetOverweight$16.00High
2/13/2018JPMorgan Chase & Co.Lower Price TargetOverweight ➝ Overweight$13.00 ➝ $9.00High
2/13/2018BenchmarkLower Price TargetBuy ➝ Buy$11.00 ➝ $10.00High
1/16/2018BenchmarkLower Price TargetBuy ➝ Buy$16.00 ➝ $11.00Medium
1/16/2018SVB LeerinkLower Price TargetOutperform ➝ Outperform$12.00 ➝ $10.00High
1/5/2018LADENBURG THALM/SH SHInitiated CoverageBuy ➝ Buy$15.00High
11/7/2017SVB LeerinkLower Price TargetOutperform$14.00 ➝ $12.00N/A
8/9/2017JPMorgan Chase & Co.Reiterated RatingOverweight$14.00 ➝ $15.00Low
4/3/2017BenchmarkReiterated RatingBuy ➝ Buy$11.00 ➝ $16.00High
2/14/2017BenchmarkUpgradeHold ➝ Buy$8.50 ➝ $11.00N/A
11/10/2016SVB LeerinkInitiated CoverageOutperform$12.00N/A
11/9/2016SVB LeerinkReiterated RatingOutperformN/A
11/8/2016BenchmarkReiterated RatingHold ➝ NeutralN/A
8/9/2016JPMorgan Chase & Co.Boost Price TargetOverweight$12.00 ➝ $14.00N/A
6/30/2016BenchmarkInitiated CoverageHold$8.50N/A
(Data available from 6/23/2016 forward)
Invitae logo
Invitae Corporation, a medical genetics company, integrates genetic information into healthcare decision-making by clinicians and patients in the United States, Canada, and internationally. The company offers genetic tests in various clinical areas, including hereditary cancer, cardiology, neurology, pediatrics, oncology, metabolic conditions, and rare diseases. It serves patients, healthcare providers, biopharma companies, and other partners. The company was formerly known as Locus Development, Inc. and changed its name to Invitae Corporation in 2012. Invitae Corporation was founded in 2010 and is headquartered in San Francisco, California.
Read More

Today's Range

Now: $33.81
Low: $33.18
High: $34.30

50 Day Range

MA: $31.14
Low: $26.09
High: $39.06

52 Week Range

Now: $33.81
Low: $25.24
High: $61.59


2,459,080 shs

Average Volume

4,180,897 shs

Market Capitalization

$6.76 billion

P/E Ratio


Dividend Yield




Frequently Asked Questions

What sell-side analysts currently cover shares of Invitae?

The following Wall Street analysts have issued stock ratings on Invitae in the last twelve months: Benchmark Co., Cowen Inc, JPMorgan Chase & Co., LADENBURG THALM/SH SH, Morgan Stanley, Oppenheimer Holdings Inc., Raymond James, SVB Leerink LLC, The Goldman Sachs Group, Inc., Wells Fargo & Company, and Zacks Investment Research.
View the latest analyst ratings for NVTA.

What is the current price target for Invitae?

9 Wall Street analysts have set twelve-month price targets for Invitae in the last year. Their average twelve-month price target is $42.44, suggesting a possible upside of 25.5%. LADENBURG THALM/SH SH has the highest price target set, predicting NVTA will reach $58.00 in the next twelve months. The Goldman Sachs Group, Inc. has the lowest price target set, forecasting a price of $33.00 for Invitae in the next year.
View the latest price targets for NVTA.

What is the current consensus analyst rating for Invitae?

Invitae currently has 5 hold ratings and 5 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe NVTA will outperform the market and that investors should add to their positions of Invitae.
View the latest ratings for NVTA.

What other companies compete with Invitae?

How do I contact Invitae's investor relations team?

Invitae's physical mailing address is 1400 16th Street, SAN FRANCISCO CA, 94103. The medical research company's listed phone number is 415-374-7782 and its investor relations email address is [email protected] The official website for Invitae is www.invitae.com.